febit Receives European Union (EU) Patent for Synthesis of Minimal Genomes
A minimal genome contains only the genetic information which is required to sustain life of a certain organism under predefined conditions. Minimal genomes help to identify essential genes and investigate the isolated activity of interesting genes in minimal cells. The synthesis of minimal genomes complements febit’s portfolio which contains groundbreaking technologies for the exploration of the genome. HybSelect, for example, is a technology for the enrichment of interesting genes for targeted resequencing. febit’s miRNA profiling enables the discovery and evaluation of new biomarker signatures for various diseases.
febit currently holds more than 20 patents and patent applications. In addition to bioanalytics, the company´s intellectual property portfolio predominantly covers the production of synthetic genes on biochips, an area where febit holds several key patents.
Most read news
Topics
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.